Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interferon alfa
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 667 for your search:
Start Over
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: HSC-MS-06-0478, OSP-24412, NCT00581425
Phase II/III Randomized Study of CDDP/5-FU vs CDDP/5-FU/IFN-A for Metastatic Pancreatic Cancer (Summary Last Modified 02/95)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 75
Sponsor:
Protocol IDs: EORTC-40924
Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 79
Sponsor:
Protocol IDs: FRE-FNCLCC-95009, EU-96026
Phase II/III Randomized Study of SCH 54031 (Polyethylene Glycol Interferon alfa-2b) Versus Interferon alfa-2b in Patients With Newly Diagnosed Chronic Phase Myelogenous Leukemia (Summary Last Modified 01/2000)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C98-026, SPRI-C98-026-054, SPRI-I98-026
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Other
Protocol IDs: 01-002-0601, NCT00205751
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 06762004, NCT00420888
Phase III Randomized Study of IFN-A with vs without 13-CRA in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 02/96)
Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: MSKCC-94004, E-2894, NCI-T93-0198D, T93-0198
Phase III Randomized Study of Maintenance Therapy with IFN-A vs Placebo for Intermediate- and High-Grade non-Hodgkin's Lymphoma in Complete or Partial Remission Following Salvage Chemotherapy (Summary Last Modified 03/1999)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C94-105/I94-105, SCH-C94-105, SCH-I94-105, NCI-V95-0665
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-30951, NCT00002737
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 75
Sponsor: Other
Protocol IDs: CDR0000064718, EORTC-18952, NCT00002763
Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
Phase III Randomized Study of Adjuvant Interferon alfa in Stage IIIB Melanoma (Summary Last Modified 09/96)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: WHO-MEL-TRIAL16, EU-95046
Combination Chemotherapy in Treating Patients With Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 59
Sponsor: NCI, Other
Protocol IDs: MDA DM95-121, P30CA016672, NCI-V96-1010, CDR0000065044, NCT00002835
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI, Other
Protocol IDs: CDR0000065146, MRC-LEUK-CML-2000, ECOG-E7995, MRC-LEUK-CML-IV, MRC-LEUK-CML-IVa, EU-96029, E7995, NCT00002868
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 10 to 70
Sponsor: NCI, Other
Protocol IDs: ID95-196, P30CA016672, MDA-ID-95196, MDA-DM-95196, NCI-G96-1089, CDR0000065188, NCT00002882
Start Over